GNH USA

Europe — EMA

Inzolfi

GNH USA supplies Inzolfi (Fingolimod), a sphingosine‑1‑phosphate receptor modulator for relapsing‑remitting and active multiple sclerosis.

Fingolimod

Request sourcing

1
Pack/s

What is Fingolimod?

Fingolimod, the active ingredient in Inzolfi, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as an oral formulation for oral use. It treats relapsing‑remitting multiple sclerosis and other active forms of multiple sclerosis in adult patients.

GNH USA supplies Inzolfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Fingolimod used for?

Inzolfi is a disease‑modifying therapy that acts on the sphingosine‑1‑phosphate pathway to manage multiple sclerosis.

Relapsing‑remitting multiple sclerosis: reduces relapse frequency and slows disability progression. Active secondary progressive multiple sclerosis: decreases disease activity and relapse risk. Clinically isolated syndrome: may lower the chance of conversion to definite multiple sclerosis.

What are the side effects of Fingolimod?

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: transient gastrointestinal discomfort. - Fatigue: general tiredness reported by many patients. - Lymphopenia: reduced lymphocyte count observed in routine labs.

Serious or Rare Side Effects: - Cardiac arrhythmia: bradycardia or heart block, especially after first dose. - Macular edema: swelling of the retina that may affect vision. - Severe infections: opportunistic or serious bacterial infections. - Liver enzyme elevation: significant increase in ALT/AST levels.

What precautions apply to Fingolimod?

Patients should be evaluated for several safety considerations before and during treatment.

Monitor lymphocyte count: perform baseline and periodic CBC to detect lymphopenia. Assess cardiac function: obtain baseline ECG and monitor heart rate after initiation. Screen for infections: ensure no active infection before starting therapy. Avoid use in pregnancy: contraindicated; effective contraception required. Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

What does Fingolimod interact with?

Fingolimod may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: contraindicated due to immunosuppression risk. - Strong CYP4F2 inhibitors: may increase fingolimod exposure. - Concomitant bradycardic agents: can exacerbate heart rate reduction.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may increase urinary retention risk. - Other immunosuppressants: additive infection risk. - Non‑live vaccines: possible reduced efficacy, monitor response.

Frequently asked questions

What is Inzolfi used for?+
Inzolfi contains fingolimod and is indicated for the treatment of relapsing‑remitting multiple sclerosis and active forms of multiple sclerosis, including active secondary progressive disease, in adult patients. It is prescribed to reduce the frequency of clinical relapses and to slow the progression of disability associated with the disease.
How does fingolimod work?+
Fingolimod is a selective modulator of sphingosine‑1‑phosphate receptors on lymphocytes. By binding to S1P1 receptors, it causes receptor internalisation, preventing lymphocytes from leaving lymph nodes. This reduces the number of circulating lymphocytes that can enter the central nervous system, thereby diminishing inflammatory attacks that lead to demyelination in multiple sclerosis.
What is the usual dose of Inzolfi?+
The dosing regimen for Inzolfi is determined by the prescribing physician based on the patient’s clinical condition, laboratory values, and applicable regulatory guidelines. The prescriber selects the appropriate strength and administration schedule, and patients should follow the healthcare professional’s instructions without deviation.
Is Inzolfi safe in pregnancy or breastfeeding?+
Fingolimod is contraindicated during pregnancy because it may cause fetal harm, and it is not recommended for breastfeeding mothers as it can be excreted in breast milk. Women of child‑bearing potential should use effective contraception and discuss family planning with their healthcare provider before starting therapy.
How do I order Inzolfi from GNH USA?+
To request Inzolfi, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.
How does Inzolfi compare with the main alternative drug?+
The primary alternative to fingolimod is dimethyl fumarate or other disease‑modifying therapies such as interferon‑β. Compared with interferon‑β, fingolimod offers oral administration and a mechanism that directly reduces lymphocyte egress, but it carries distinct safety considerations, including cardiac monitoring and infection risk, which must be weighed by the treating physician.
What are the storage and handling requirements for Inzolfi?+
Inzolfi should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in bathrooms or near heat sources. No refrigeration is required for this oral formulation.
How is Inzolfi administered?+
Inzolfi is taken orally, usually as a tablet swallowed whole with water. The medication is intended for once‑daily use, and patients should take it at the same time each day to maintain consistent blood levels. It may be taken with or without food as directed by the prescribing clinician.
What are the most serious risks to watch for while taking Inzolfi?+
The most serious risks associated with fingolimod include severe infections, cardiac events such as bradyarrhythmia or heart block, macular edema affecting vision, and significant liver enzyme elevations. Patients should promptly report persistent fever, chest pain, visual changes, or jaundice to their healthcare provider.
Who should not use Inzolfi?+
Inzolfi is contraindicated in patients with known hypersensitivity to fingolimod, those with active infections, severe cardiac conditions, or a history of stroke. It is also prohibited during pregnancy and in women who are breastfeeding. Individuals with significant liver impairment or uncontrolled hypertension should be evaluated carefully before use.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Fingolimod
Route
Oral Use
Manufacturer
1a Farma A/S
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU